PSNL — Personalis, Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1527753 ·
Last close
$14.80
Market Cap
$1.60B
52W High
$18.89
52W Low
$4.95
ADV30
2,496,092
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 25,596,000 | 6,570,000 | -35,518,000 | -33,801,000 | 291,600,000 | 98,271,000 | 78,930,000 |
| Jun 2026 | 22,357,000 | 4,743,000 | -33,591,000 | -31,683,000 | 312,135,000 | 93,968,000 | 76,974,000 |
| Mar 2026 | 15,472,000 | 281,000 | -32,161,000 | -30,032,000 | 325,395,000 | 73,594,000 | 70,630,000 |
| Dec 2025 | 17,345,000 | 1,900,000 | -25,266,000 | -23,812,000 | 334,164,000 | 124,245,000 | 72,979,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-97,566,000
Investing CF
$1,783,000
Financing CF
$144,082,000
CapEx
$-10,124,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.17
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-726,776,000
Inventory
$6,468,000
Receivables
$18,035,000
ST Investments
$92,331,000
EBIT TTM
$-119,110,000
Pretax Income TTM
$-119,295,000
Interest Exp TTM
$185,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$80,770,000
EBITDA
$-116,810,000
Free Cash Flow
$-59,346,624
Enterprise Value
$1,558,294,272
Total Cash
$190,602,000
Total Debt
$37,200,000
Shares Out
108,403,814
Trailing EPS
$-1.16
Book Value
$1.96
ROE
-62.1%
ROA
-29.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 69,648,000 | -88,057,000 | -81,270,000 | 334,164,000 | 72,979,000 | 261,185,000 | -74,946,000 |
| Dec 2024 | 84,614,000 | -68,267,000 | -81,284,000 | 270,268,000 | 67,311,000 | 202,957,000 | -45,150,000 |
| Dec 2023 | 73,481,000 | -96,294,000 | -108,296,000 | 225,099,000 | 95,658,000 | 129,441,000 | -56,258,000 |
| Dec 2022 | 65,047,000 | -115,531,000 | -113,315,000 | 292,700,000 | 74,561,000 | 218,139,000 | -70,233,000 |
TTM Snapshot
Revenues TTM
$69,669,000
NetIncome TTM
$-107,179,000
OpCashFlow TTM
—
Assets (Latest)
$312,135,000
Forward EPS
$-0.97
Max Pain — expiry 2027-01-15
max pain strike: $10.00 · spot: $14.98 · call oi: 32,346 · put oi: 842
Expected Move to 2027-01-15:
±$2.43
(16.22%) —
implied range
$12.55 –
$17.41
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNDA | SONIDA SENIOR LIVING, INC. | $1.60B | $32.57 | — |
| TDOC | Teladoc Health, Inc. | $1.55B | $8.49 | — |
| HCSG | HEALTHCARE SERVICES GROUP INC | $1.66B | $24.69 | — |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.45B | $97.34 | — |
| WGS | GeneDx Holdings Corp. | $1.42B | $47.29 | — |
News headlines (Yahoo Finance, 1h cache)
Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega
2026-11-09 15:40 · Yahoo
PSNL Deal Alert: Personalis $16.25 per Share Merger Under Investigation – Contact BFA Law about the Pending Merger Investigation
2026-11-09 10:36 · Yahoo
Did Wider Losses Just Shift Personalis (PSNL) Stock Investment Narrative?
2026-11-07 07:12 · Yahoo
Personalis: Q3 Earnings Snapshot
2026-11-04 21:28 · Yahoo
Personalis Reports Third Quarter Results
2026-11-04 21:01 · Yahoo
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
2026-10-27 13:28 · Yahoo
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
2026-10-21 10:00 · Yahoo
Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years
2026-10-20 06:11 · Yahoo
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
2026-11-03 14:00 · Yahoo
What Tempus AI (TEM) Said on Its Q3 Earnings Call
2026-11-02 16:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.